The approval gives Boehringer and Lilly an opportunity to regain ascendency in the SGLT2 market after a prolonged period of sustained growth for AZ's Forxiga (dapagliflozin) – known as Farxiga ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback